Congress passed a Farm Bill in 2018 that includes historic provisions that legalize hemp, the low THC cultivars of the Cannabis sativa L. species. When the president signed this landmark legislation into law, it changed how hemp and hemp-derived products like cannabidiol (CBD) are regulated in the U.S.
To help the herbal products industry understand the new regulatory landscape, AHPA produced a free Status Report and webinar to answer industry questions.
Free Status Report
AHPA worked with legal and industry experts to develop a new, free resource titled Status Report: Marketing of hemp and cannabidiol (CBD) products in the United States following passage of the 2018 Farm Bill.
This document provides concise and up-to-date information on the status of such operations and products as soon as this legislation is adopted as federal law and taking into account other current and relevant laws and regulations.
Because of the herbal product industry’s broad interest in the impact of this legislation on hemp and CBD, AHPA is distributing this information before the bill has been signed into law. The 2018 Farm Bill has been passed by the Senate and House, but still needs to be signed into law by the President. We are not aware of any indications that successful and timely completion of this is in doubt. AHPA will notify those receiving this information in the unlikely event that circumstances change.
On Demand Webinar
Recorded on Dec. 19, this webinar presents more than two hours of expert information on how the Farm Bill could affect companies that want to cultivate hemp crops or sell consumer goods that contain hemp and hemp-derived ingredients, including CBD. It also includes an extended Q&A session that answers to attendees' specific questions.
- Recorded: December 19, 2018
- Duration: 2+ hours
- Cost: $50 for members -- $100 for non members
Veteran herbal industry experts provide insiders' views of the evolving regulatory landscape for companies growing, manufacturing or selling hemp and products with hemp-derived ingredients, including CBD.
- Michael McGuffin, President, AHPA
- Jane Wilson, Director of Program Development, AHPA
- Holly Johnson, Ph.D., Chief Science Officer, AHPA
- Will Woodlee, Esq., Partner, Kleinfeld, Kaplan & Becker
- Pete Evich, Vice President, Van Scoyoc Associates (Q&A)
- Tony Young, Esq., Partner, Kleinfeld, Kaplan & Becker (Q&A)